SCHEMBL10147646

SCHEMBL10147646

C[C@H](NC(=O)OC(C)(C)C)c1nc2c(Cl)cccc2cc1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
ATM Q13315 1/20 0.39
TP53 P04637 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 2/20 0.37
MITF O75030 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CTSL P07711 1/20 0.37
TRPA1 O75762 1/20 0.36
LCK P06239 2/20 0.36
GABRB1 P18505 1/20 0.36
GABRB2 P47870 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1694884 1.00 MAPT (0.39) MAPTATMTP53SMN1; SMN2LMNA
SCHEMBL10146874 0.87 MAPT (0.39) MAPTATMTP53LMNAMITF
SCHEMBL1694878 0.87 MAPT (0.39) MAPTATMTP53LMNAMITF
SCHEMBL10147129 0.87 MAPT (0.40) MAPTTP53SMN1; SMN2LMNAHPGD
SCHEMBL21445289 0.81 TP53 (0.42) MAPTATMTP53SMN1; SMN2LMNA
SCHEMBL16630523 0.79 PIK3CD (0.40) MAPTATMTP53SMN1; SMN2HPGD
SCHEMBL1694887 0.76 NQO2 (0.47) MAPTTP53SMN1; SMN2LMNAHPGD
SCHEMBL1695324 0.76 MEN1 (0.40) MAPTATMLMNAMITFHPGD
SCHEMBL1694904 0.76 MEN1 (0.40) MAPTATMLMNAMITFHPGD
SCHEMBL1694635 0.75 TSHR (0.40) HPGDTSHRLIPGCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130085131-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-04 US disclosed
US-20130085131-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-04 US disclosed
US-20130085131-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-04 US disclosed
WO-2012003274-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085131-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, SSB, BCL9 MAPT 1990/4885ATM 949/4885TP53 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.